Clinical Trials in Austin

Showing 3181-3200 of 7,312 trials

MCI: CPAP Treatment of OSA (Memories2)

NCT03113461

The purpose of this project is to determine whether obstructive sleep apnea (OSA) treatment with positive airway pressure therapy (CPAP) can delay the progression of cognitive impairment in patients with amnestic Mild Cognitive Impairment (MCI) as measured by cognitive testing, and brain magnetic resonance imaging (MRI) scans. Study participants will be assessed at baseline, six-month (cognitive tests only) and one-year follow-up.

Mild Cognitive ImpairmentSleep Apnea, Obstructive

University of Pennsylvania327 participantsStarted Jan 2018

St Louis, Missouri, United States • Philadelphia, Pennsylvania, United States • Austin, Texas, United States +1 more locations

TERMINATEDPhase 2< 1 mile

A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia

NCT03965091

The primary objective of the study is to estimate the treatment effect of fremanezumab administered subcutaneously (SC) in reducing pain in adult participants with fibromyalgia (FM). A secondary objective is to evaluate the effect of fremanezumab on other efficacy measures, including pain, quality of life, sleep, fatigue, improvement in health, physical functioning, and mood. Another secondary objective is to evaluate the safety and tolerability of fremanezumab administered SC in adult participants with FM. The total duration of participant participation in the study is planned to be 21 weeks, consisting of a screening period of up to 5 weeks (ranging from 17 to 35 days), and a double-blind treatment period of 16 weeks.

Fibromyalgia

Teva Branded Pharmaceutical Products R&D, Inc.189 participantsStarted Jul 2019

Birmingham, Alabama, United States • Huntsville, Alabama, United States • Mesa, Arizona, United States +46 more locations

MCI: CPAP Treatment of OSA (Memories2)

A Study to Test the Effectiveness and Safety of Fremanezumab on Participants With Fibromyalgia

Find Trials by Condition in Austin

Impact of Supplements on Stress Markers

Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)

Thrombosomes® in Bleeding Thrombocytopenic Patients

N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Nanocrystalline Gold to Treat Remyelination Failure in Chronic Optic Neuropathy In Multiple Sclerosis

A Study of Lanadelumab in Persons With Hereditary Angioedema (HAE) Type I or II in North America

Comparison of Sleep Apnea Assessment Strategies to Maximize TBI Rehabilitation Participation and Outcome

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

PTX-COVID19-B, an mRNA Humoral Vaccine, Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Demonstrate the Safety, Tolerability, and Immunogenicity of PTX-COVID19-B in Comparison to the Pfizer-BioNTech COVID-19 Vaccine.